Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2019 | Obesity | Research

Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats

Authors: Xin Tao, Lisi Cai, Lei Chen, Shuqi Ge, Xuanying Deng

Published in: Journal of Ovarian Research | Issue 1/2019

Abstract

Aims

This study was designed to evaluate the protective effects of AMPKα and SIRT1 on insulin resistance in PCOS rats, and to illuminate the underlying mechanisms.

Methods

An in vitro PCOS model was established by DHEA (6 mg/(100 g•d)), and the rats were randomly divided into the metformin group (MF group, n = 11), the exenatide group (EX group, n = 11), the PCOS group (n = 10), and the normal control group (NC group, n = 10). The MF group was administered MF 300 mg/(kg•d) daily. The EX group was subcutaneously injected EX 10μg/(kg•d) daily. After 4 weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured. Western and Real-time PCR were used to determine the expression of AMPKα and SIRT1 in the ovaries of each group.

Results

After 4 weeks of drug intervention, compared with untreated PCOS group, EX group and MF group had visibly decreased body weight (222.64 ± 16.57, 218.63 ± 13.18 vs 238.30 ± 12.26 g, P = 0.026), fasting blood glucose (7.71 ± 0.72, 8.17 ± 0.54 vs 8.68 ± 0.47 mmol/L, P < 0.01), HOMA-IR (8.26 ± 2.50, 7.44 ± 1.23 vs 12.66 ± 1.44, P < 0.01) and serum androgen (0.09 ± 0.03, 0.09 ± 0.03 vs 0.53 ± 0.41 ng/ml, P < 0.01) and the expressions of AMPKα and SIRT11 were increased progressively (P < 0.05).

Conclusions

Both metformin and exenatide can improve the reproductive and endocrine functions of rats with PCOS via the AMPKα-SIRT1 pathway, which may be the molecular mechanism for IR in PCOS and could possibly serve as a therapeutic target.

Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477–88. https://doi.org/10.1093/humupd/dmp008.CrossRefPubMed

Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Women Health. 2009;5:529–42. https://doi.org/10.2217/whe.09.39.CrossRef

Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110:794–809. https://doi.org/10.1016/j.fertnstert.2018.08.021.CrossRefPubMed

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162:193–212. https://doi.org/10.1530/EJE-09-0733.CrossRefPubMed

Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–54. https://doi.org/10.1016/0026-0495(94)90209-7.CrossRefPubMed

Kim YD, Park K, Lee Y, Park Y, Kim D, Nedumaran B, et al. AMP-activated protein kinase – dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57:306–14. https://doi.org/10.2337/db07-0381.Additional.CrossRefPubMed

Lyndal RH, Naveed S, Jane EN, Richard F. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90:4593–8. https://doi.org/10.1210/jc.2004-2283.CrossRef

Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304:368–71. https://doi.org/10.1038/304368a0.CrossRefPubMed

Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–42. https://doi.org/10.1038/nrendo.2012.140.CrossRefPubMed

10.

Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):767–74. https://doi.org/10.1111/cen.13454.CrossRef

11.

Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670–8. https://doi.org/10.1210/jc.2008-0115.CrossRefPubMed

12.

Tao X, Chen L, Cai L, Ge S, Deng X. Regulatory effects of the AMPKα-SIRT1 molecular pathway on insulin resistance in PCOS mice: an in vitro and in vivo study. Biochem Biophys Res Commun. 2017;494:615–20. https://doi.org/10.1016/j.bbrc.2017.09.154.CrossRefPubMed

13.

Tao X, Zhang X, Ge SQ, Zhang EH, Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015;8(7):8276–83.PubMedPubMedCentral

14.

Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod. 1986;2:81–7. https://doi.org/10.1093/oxfordjournals.humrep.a136365.CrossRef

15.

Veltman-Verhulst SM, Boivin J, et al. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update. 2012;18:638–51. https://doi.org/10.1093/humupd/dms029. CrossRefPubMed

16.

Neven ACH, Laven J, Teede HJ, Boyle JA. A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. Semin Reprod Med. 2018;36:5–12. https://doi.org/10.1055/s-0038-1668085.CrossRefPubMed

17.

Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12:324–32.CrossRef

18.

Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619–31. https://doi.org/10.1093/humrep/dew243.CrossRefPubMed

19.

Tobergte DR, Curtis S. Metformin inhibits intra-cellular lipid accumulation in the murine preadipocyte cell line, 3T3-L1. J Chem Inf Model. 2013;53:1689–99. https://doi.org/10.1017/CBO9781107415324.004.CrossRef

20.

Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DePinho RA, et al. Medicine: the kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (80- ). 2005;310:1642–6. https://doi.org/10.1126/science.1120781.CrossRef

21.

Arunachalam G, Samuel SM, Marei I, Ding H, Triggle CR. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol. 2014;171:523–35. https://doi.org/10.1111/bph.12496.CrossRefPubMed

22.

Canto´ C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056–60. https://doi.org/10.1038/nature07813.CrossRefPubMedPubMedCentral

23.

Rogacka D, Audzeyenka I, Rychłowski M, Rachubik P, Szrejder M, Angielski S, et al. Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. Biochim Biophys Acta - Mol Basis Dis. 2018;1864:115–25. https://doi.org/10.1016/j.bbadis.2017.10.014.CrossRefPubMed

24.

Nelson LE, Valentine RJ, Cacicedo JM, Gauthier M-S, Ido Y, Ruderman NB. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Physiol. 2012;303:C4–13. https://doi.org/10.1152/ajpcell.00296.2011.CrossRef

25.

Shrestha N, Araújo F, Shahbazi MA, Mäkilä E, Gomes MJ, Airavaara M, et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. J Control Release. 2016;232:113–9. https://doi.org/10.1016/j.jconrel.2016.04.024.CrossRefPubMed

26.

Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, et al. The GLP-1 receptor agonists exenatide and liraglutide activate glucose transport by an AMPK-dependent mechanism. J Transl Med. 2016;14:1–13. https://doi.org/10.1186/s12967-016-0985-7.CrossRef

27.

Thorens B. Expression cloning of the pancreatic J8 cell receptor for the gluco-incretin hormone glucagon-like peptide 1 (insulin secretion/non-insulin-dependent diabetes mellitus/entero-insular axis/G proteins/cAMP). Cell Biol. 1992;89:8641–5.

Title: Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats
Authors: Xin Tao
Lisi Cai
Lei Chen
Shuqi Ge
Xuanying Deng
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Obesity
Obesity
Insulins
Polycystic Ovary Syndrome
Metformin
Exenatide
Polycystic Ovary Syndrome
Insulins
Published in: Journal of Ovarian Research / Issue 1/2019
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-019-0555-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats

Abstract

Aims

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis

Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

Quercetin: a natural compound for ovarian cancer treatment

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial